New treatment option for ovarian cancer: PARP inhibitors
about
Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatmentNext-Generation Sequencing-based genomic profiling of brain metastases of primary ovarian cancer identifies high number of BRCA-mutations.PARP Inhibitors in Reproductive System Cancers: Current Use and Developments.The Diagnostic and Prognostic Potential of microRNAs in Epithelial Ovarian Carcinoma.Prediction of therapy response in ovarian cancer: Where are we now?Targeted therapy of ovarian cancer including immune check point inhibitor.Improving radiotherapy in cancer treatment: Promises and challenges.Human Antibody Fusion Proteins/Antibody Drug Conjugates in Breast and Ovarian CancerIdentification of cancer genes that are independent of dominant proliferation and lineage programs.Outcomes of Treatment for Malignant Peripheral Nerve Sheath Tumors: Different Clinical Features Associated with Neurofibromatosis Type 1.Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature.Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer.Combination of a hypomethylating agent and inhibitors of PARP and HDAC traps PARP1 and DNMT1 to chromatin, acetylates DNA repair proteins, down-regulates NuRD and induces apoptosis in human leukemia and lymphoma cells.Geraniin suppresses ovarian cancer growth through inhibition of NF-κB activation and downregulation of Mcl-1 expression.Precision Medicine for CRC Patients in the Veteran Population: State-of-the-Art, Challenges and Research Directions.The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma.
P2860
Q28075761-2E9AAAFA-C2E1-4490-AE1F-A1DD76FF02B1Q36369910-109A4189-D229-4077-8508-7A13CF839438Q37607283-DA52EEF7-0A9F-4C32-806B-CC8541D0DD93Q38975570-65073004-55E0-4C84-9C02-93C486A3DAF5Q39263260-531549DD-B299-401C-BF0A-242D37BF2133Q41607677-12328105-1D04-472B-9CE9-C049CFC7FDDBQ41899048-EFB7F15C-79FD-45EE-BD92-ABF3234DC2C7Q42660155-03950379-E5E5-4612-9EFF-F9711108ADE0Q47327357-F547D9DE-BC6A-4EE9-85D2-4D00EB8A16F2Q47593298-E6F4DCA6-3113-4C1B-9BA0-BC77AEBA08EDQ48110433-EDD34554-E847-40A9-9F06-6576C30140A0Q48534871-86B7CD42-BF92-4D9A-AE2C-BFCECCA54A2FQ49989774-3B9D254F-73C3-4AB0-A9CA-AA54DCAB49BDQ50955345-1ED37D02-6C3A-490A-81B4-F36B0FB17468Q52639286-1FE51C95-6256-4954-B3FC-229E0E854FACQ55037005-2EEE7CB2-83E9-4605-8909-314F6BC49FA5
P2860
New treatment option for ovarian cancer: PARP inhibitors
description
2016 nî lūn-bûn
@nan
2016 թուականին հրատարակուած գիտական յօդուած
@hyw
2016 թվականին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
New treatment option for ovarian cancer: PARP inhibitors
@ast
New treatment option for ovarian cancer: PARP inhibitors
@en
New treatment option for ovarian cancer: PARP inhibitors
@nl
type
label
New treatment option for ovarian cancer: PARP inhibitors
@ast
New treatment option for ovarian cancer: PARP inhibitors
@en
New treatment option for ovarian cancer: PARP inhibitors
@nl
prefLabel
New treatment option for ovarian cancer: PARP inhibitors
@ast
New treatment option for ovarian cancer: PARP inhibitors
@en
New treatment option for ovarian cancer: PARP inhibitors
@nl
P2860
P3181
P1476
New treatment option for ovarian cancer: PARP inhibitors
@en
P2093
Alice P Chen
Robert S Meehan
P2860
P2888
P3181
P356
10.1186/S40661-016-0024-7
P407
P577
2016-01-01T00:00:00Z
P6179
1013860507